Abstract: This invention relates to compounds of formula II: wherein R1, R2, ProtSH, and ProtNH are as defined, to processes for the synthesis of ecteinascidins of formula I from compounds of formula II, and to processes for the synthesis of compounds of formula II.
Type:
Application
Filed:
May 24, 2011
Publication date:
March 14, 2013
Applicant:
Pharma Mar, S.A.
Inventors:
Ma Jesús Martín López, Andrés Francesch Solloso, Maria del Carmen Cuevas Marchante
Abstract: Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus Lithoplocamia, species lithistoides, and derivatives thereof are provided.
Type:
Grant
Filed:
June 15, 2007
Date of Patent:
December 4, 2012
Assignee:
Pharma Mar, S.A.
Inventors:
Ma Jesús Martín López, Laura Coello Molinero, José Fernando Reyes Benítez, Alberto Rodríguez Vicente, María Garranzo García-Ibarrola, Carmen Murcia Pérez, Andrés Francesch Solloso, Francisco Sánchez Sancho, María del Carmen Cuevas Marchante, Rogelio Fernández Rodríguez
Abstract: The present invention relates to combinations of aplidine or aplidine analogues with other titumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.
Type:
Grant
Filed:
February 28, 2007
Date of Patent:
September 4, 2012
Assignee:
Pharma Mar, S.A.
Inventors:
Glynn Thomas Faircloth, Pablo Manuel Aviles Marin, Doreen LePage, Jesus San Miguel Izquierdo, Atanasio Pandiella
Abstract: ET-743 is used in the preparation of a medicament for an effective treatment of a tumour by combination therapy employing ET-743 with another drug.
Type:
Application
Filed:
December 30, 2011
Publication date:
May 3, 2012
Applicant:
PHARMA MAR, S.A.
Inventors:
Naoto Takahashi, Steve Weitman, Maurizio D'Incalci, Glynn Thomas Faircloth, Rafaella Giavazzi, Andreas Gescher
Abstract: Et 743 is used in the preparation of a medicament for the treatment of the human body for cancer.
Type:
Grant
Filed:
June 28, 2007
Date of Patent:
February 21, 2012
Assignee:
Pharma Mar, S.A.
Inventors:
Esteban Cvitkovich, George Daniel Demetri, Cecilia Guzman, Jose Jimeno, Luis Lopez Lazaro, Jean Louis Misset, Chris Twelves, Daniel D. Von Hoff
Abstract: A compound of general formula (I) wherein, R11, R12, R13, R14, R15, W, Y, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.
Type:
Application
Filed:
December 19, 2008
Publication date:
February 16, 2012
Applicant:
PHARMA MAR, S.A.
Inventors:
Alberto Rodriguez Vicente, Maria Garranzo Garcia- Ibarrola, Carmen Murcia Perez, Francisco Sanchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digon Juarez
Abstract: Derivatives of Et-743 or Et-770 or Et-729 are provided. The derivatives are of the general formula Ia.: wherein the substituent groups take various permitted meanings.
Type:
Grant
Filed:
April 6, 2010
Date of Patent:
December 13, 2011
Assignee:
Pharma Mar, S.A.
Inventors:
Valentin Martinez, Maria Flores, Pilar Gallego, Carmen Cuevas, Simon Munt, Ignacio Manzanares
Abstract: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group.
Type:
Grant
Filed:
December 22, 2006
Date of Patent:
September 6, 2011
Assignee:
Pharma Mar, S.A.
Inventors:
Ignacio Manzanares, Carmen Cuevas, Marta Perez, Maria Jesus Martin, Alberto Rodriguez, Simon Munt
Abstract: Antitumoral compounds of Formula I, and pharmaceutically acceptable salts, derivatives, tautomers, prodrugs or stereoisomers thereof useful as antitumour agents.
Type:
Application
Filed:
December 10, 2008
Publication date:
August 25, 2011
Applicant:
PHARMA MAR, S.A.
Inventors:
Judit TULLA-PUCHE, Eleonora MARCUCCI, Núria BAYÓ-PUXAN, Fernando ALBERICIO, María del Carmen CUEVAS MARCHANTE
Abstract: Anticancer compounds of general formula I: wherein R1-R11 take permitted meanings for use in the treatment of cancer.
Type:
Application
Filed:
July 16, 2009
Publication date:
May 5, 2011
Applicant:
PHARMA MAR, S.A.
Inventors:
Raquel Rodríguez Acebes, Rogelio Fernández Rodríguez, José Fernando Reyes Benítez, Ma Jesús Martín López, Isabel Marco Martínez, Isabel Digón Juárez, Maria del Carmen Cuevas Marchante, Andrés Francesch Solloso
Abstract: This invention relates to antitumoral ecteinascidin derivatives that contain a fused ecteinascidin five ring system with a 1,4-bridge having the structure of formula (VIa) or (VIb) as described herein and compounds in which the —NH2 or —OH of the 1,4-bridge is derivatized, and related pharmaceutical compositions and methods. Such ecteinascidin derivatives include, but are not limited to, those compounds having formula (XVIIb): in which R1 and R4 together form a group of formula (VIa) or (VIb) as described herein, and R5, R7, R8, R14a, R14b, R15, and R21 are as defined herein.
Type:
Grant
Filed:
April 10, 2007
Date of Patent:
April 5, 2011
Assignee:
Pharma Mar, S.A.
Inventors:
Maria Flores, Andres Francesh, Pilar Gallego, Jose Luis Chicharro, Maria Zarzuelo, Carolina Fernandez, Ignacio Manzanares
Abstract: The present invention relates to combinations of PM00104 with other anticancer drugs, and the use of these combinations in the treatment of cancer.
Type:
Application
Filed:
May 18, 2009
Publication date:
March 24, 2011
Applicant:
Pharma Mar, S.A.
Inventors:
Doreen LePage, Pablo Manuel Aviles Marin, Maria Jose Guillen Navarro
Abstract: A compound of general formula (I) wherein A, Y, W, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.
Type:
Application
Filed:
December 19, 2008
Publication date:
February 10, 2011
Applicant:
PHARMA MAR, S.A.
Inventors:
Alberto Rodriguez Vicente, María Garranzo García-Ibarrola, Carmen Murcia Pérez, Francisco Sánchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digón Juárez
Abstract: The present invention relates to combinations of PM02734 with another anticancer drug selected from Cisplatin, Gemcitabine, Paclitaxel, Oxaliplatin, 5-Fluorouracil, Trabectedin, Rapamycin, and Sunitinib, and the use of these combinations in the treatment of cancer.
Type:
Application
Filed:
March 6, 2009
Publication date:
January 20, 2011
Applicant:
Pharma Mar S.A.
Inventors:
Santiago Ramón Y Cajal Agüeras, Javier Hernández Losa, José Mª Jimeno Doñaque, Eric Raymond
Abstract: The present invention relates to colloidal metal nanoparticles conjugated with Kahalalide F, or an analogue thereof, and their use in the treatment of cancer. The invention also relates to a method for increasing the antitumoral activity of Kahalalide F, or an analogue thereof, which comprises conjugating the Kahalalide F, on an analogue thereof, with a colloidal metal nanoparticle.
Type:
Application
Filed:
January 30, 2009
Publication date:
December 23, 2010
Applicant:
PHARMA MAR, S.A.
Inventors:
Leticia Hosta, Mateu Pla, Luis Javier Cruz, Marcelo Kogan, Fernando Albericio
Abstract: Antitumoral compounds of Formula I, and pharmaceutically acceptable salts, derivatives, tautomers, prodrugs or stereoisomers thereof useful as antitumour agents.
Type:
Application
Filed:
December 10, 2008
Publication date:
November 18, 2010
Applicant:
Pharma Mar, S.A.
Inventors:
Judit Tulla-Puche, Eleonora Marcucci, Núria Bayo-Puxan, Fernando Albericio, Maria Del Carmen Cuevas Marchante